Cencora (COR) fundamentals: P/E, valuation, undervalued?
Cencora · Health Care · ref. ETF XLV · price $321.23
In short — Cencora trades at 24.3× earnings (P/E), 16.2× forward, with a net margin of 0.8 % and revenue growth of +5 %. Read: Fairly valued (P/E 16 in line with ~12% growth (PEG 1.4)).
Is Cencora stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$321.23+10.8% over range
Aug 28, 25low $252.74 · high $374.75Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
73% recommend buying · 11 analysts
Valuation : Fairly valued — P/E 16 in line with ~12% growth (PEG 1.4)
Valuation
24.3
P/E (price/earnings)
16.2
Forward P/E
2.05
PEG
20.1
Price/book (P/B)
$61.3B
Market cap
13.20
EPS
Profitability & growth
0.8 %
Net margin
+5 %
Revenue growth
+12 %
Earnings growth
$14.5B
Total debt
Cencora income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $238.6B | $1.7B | 0.7 % |
| 2023 | $262.2B | $1.7B | 0.7 % |
| 2024 | $294.0B | $1.5B | 0.5 % |
| 2025 | $321.3B | $1.6B | 0.5 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Cencora's P/E and is the stock undervalued? What's a good P/E?
Cencora's P/E is 24.3 (forward 16.2). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Fairly valued".
Is Cencora profitable?
Cencora has a net margin of 0.8 % (EPS 13.20). The company is profitable.
Is COR stock expensive?
Our read: "Fairly valued" — P/E 16 in line with ~12% growth (PEG 1.4). Cross-check with growth and sector.
💬 A question about Cencora? The JPI assistant answers using our backtest data.